PPD to present at Late Phase Drug Development conference
(Wilmington, N.C.) PPD, Inc. (Nasdaq: PPDI) today announced Deborah Covington, Dr.P.H., global head of observational studies and pregnancy registries, will join a panel of experts at the Late Phase Drug Development World Americas conference in Princeton, N.J., to discuss the methodologies for monitoring fetal outcomes associated with drug exposure in pregnancy.
Dr. Covington will define pregnancy registries and discuss challenges, strengths and weaknesses associated with these registries. With more than 30 years of clinical research experience in epidemiology, maternal and child health, Dr. Covington provides leadership and direction to PPD’s late stage research group in the conduct of registries and observational studies with a particular emphasis on global pregnancy registries.
She will be joined by Alec Walker, M.D., Dr.P.H., principal of World Health Information Science Consultants, LLC (WHISCON), and adjunct professor of epidemiology at Harvard School of Public Health. Dr. Walker is a world-renowned expert in observational studies and the safety of drugs, devices, vaccines and medical procedures. His talk will highlight the benefits and challenges associated with longitudinal record linkage studies. The presentation is Thursday, March 25, at 8 a.m. ET.
PPD and WHISCON created an alliance last year to jointly market their observational study and drug safety expertise in epidemiology and risk management services to biomedical companies, insurers and government agencies worldwide.
Late phase drug development is growing at approximately 20 percent annually because of concerns about the safety of approved drugs and the need to evaluate real world safety and effectiveness of marketed drugs. The Late Phase Drug Development World Americas conference is the first strategic forum in the United States to address major challenges in conducting strategic and compliant late stage studies.
PPD is a leading global contract research organization, celebrating 25 years of providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 41 countries and more than 10,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.

